限时广告
Technical Guide proton heavy ion therapy→
WhatsApp: +8615316519879 · [email protected]

Bispecific Antibodies in China: Dose, Accessibility and Risk

Clinical Trials & Advanced Therapies

Bispecific antibodies redirect T cells toward a tumour target by binding two antigens at once. Several are approved internationally and a growing number are in Chinese trials. For patients, the two questions that matter most are whether the specific construct is available, and whether the centre can manage the toxicities it causes.

Why the exact construct matters

"Bispecific" describes a format, not a drug. Half-life, target pair, affinity and the presence of an Fc domain all change the dosing schedule and the toxicity profile. Two agents with similar targets can require very different monitoring. Any discussion should name the compound and the protocol, not the category.

Toxicities that define the care setting

  • Cytokine release syndrome — fever, hypotension, hypoxia; grading determines management, and step-up dosing is used to reduce severity.
  • Neurological toxicity — confusion, tremor, aphasia; requires assessment rather than assumption.
  • Infection risk — prolonged hypogammaglobulinaemia with some agents, and prophylaxis is often required.
  • Local reactions — common with subcutaneous formats.

These are manageable in a centre that does this routinely and dangerous in one that does not. The presence of a defined escalation protocol, close inpatient monitoring for the first doses, and staff who recognise early CRS are more important than the drug's published response rate.

Access questions to settle first

  • Is the agent approved in China for this indication, and is it on the hospital formulary?
  • If it is in a trial, what phase and what comparator?
  • Who covers the cost of tocilizumab, immunoglobulin and admissions for toxicity management?
  • What is the step-up dosing schedule, and how many inpatient days does it require?

Next step: send the diagnosis, target testing results and prior treatment lines, and we will confirm which constructs are realistically accessible for this case.

Explore Our Medical Guides